Guangdong Marubi Biotechnology Co., Ltd. (603983.SS)
CNY 39.45
(-1.33%)
CNY 39.45
(-1.33%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.02 Billion CNY | 22.7% |
| 2022 | 838.63 Million CNY | 39.04% |
| 2021 | 603.18 Million CNY | -24.07% |
| 2020 | 794.43 Million CNY | 3.66% |
| 2019 | 766.4 Million CNY | 4.27% |
| 2018 | 735.02 Million CNY | 14.31% |
| 2017 | 642.99 Million CNY | -0.74% |
| 2016 | 647.79 Million CNY | -0.32% |
| 2015 | 649.88 Million CNY | 8.77% |
| 2014 | 597.48 Million CNY | 22.9% |
| 2013 | 486.14 Million CNY | 3.47% |
| 2012 | 469.81 Million CNY | 4.65% |
| 2011 | 448.94 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 991.3 Million CNY | 6.45% |
| 2024 Q2 | 931.19 Million CNY | 11.82% |
| 2024 Q1 | 832.74 Million CNY | -19.08% |
| 2023 Q3 | 730.35 Million CNY | -24.34% |
| 2023 Q2 | 965.34 Million CNY | 16.84% |
| 2023 Q1 | 826.21 Million CNY | -1.48% |
| 2023 FY | 1.02 Billion CNY | 22.7% |
| 2023 Q4 | 1.02 Billion CNY | 40.9% |
| 2022 FY | 838.63 Million CNY | 39.04% |
| 2022 Q3 | 568.47 Million CNY | -8.98% |
| 2022 Q2 | 624.58 Million CNY | 17.32% |
| 2022 Q1 | 532.38 Million CNY | -11.74% |
| 2022 Q4 | 838.63 Million CNY | 47.53% |
| 2021 Q4 | 603.18 Million CNY | 8.9% |
| 2021 Q2 | 797.59 Million CNY | 9.73% |
| 2021 Q1 | 726.85 Million CNY | -8.51% |
| 2021 FY | 603.18 Million CNY | -24.07% |
| 2021 Q3 | 553.89 Million CNY | -30.55% |
| 2020 Q3 | 668.66 Million CNY | -13.56% |
| 2020 Q4 | 794.43 Million CNY | 18.81% |
| 2020 FY | 794.43 Million CNY | 3.66% |
| 2020 Q1 | 623.61 Million CNY | -18.63% |
| 2020 Q2 | 773.56 Million CNY | 24.05% |
| 2019 Q4 | 766.4 Million CNY | 6.53% |
| 2019 FY | 766.4 Million CNY | 4.27% |
| 2019 Q1 | 656.3 Million CNY | -10.71% |
| 2019 Q3 | 719.41 Million CNY | 5.77% |
| 2019 Q2 | 680.16 Million CNY | 3.64% |
| 2018 Q1 | - CNY | 0.0% |
| 2018 Q4 | 735.02 Million CNY | 0.0% |
| 2018 FY | 735.02 Million CNY | 14.31% |
| 2017 FY | 642.99 Million CNY | -0.74% |
| 2016 FY | 647.79 Million CNY | -0.32% |
| 2015 FY | 649.88 Million CNY | 8.77% |
| 2014 FY | 597.48 Million CNY | 22.9% |
| 2013 FY | 486.14 Million CNY | 3.47% |
| 2012 FY | 469.81 Million CNY | 4.65% |
| 2011 FY | 448.94 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Liuzhou Liangmianzhen Co., Ltd. | 505.75 Million CNY | -103.467% |
| Shanghai Jahwa United Co., Ltd. | 3.76 Billion CNY | 72.662% |
| Henan Rebecca Hair Products Co., Ltd. | 2.53 Billion CNY | 59.368% |
| Perfect Group Corp., Ltd | 765.94 Million CNY | -34.348% |
| RUNBEN BIOTECHNOLOGY | 97.61 Million CNY | -954.206% |
| Proya Cosmetics Co.,Ltd. | 2.91 Billion CNY | 64.715% |
| Lafang China Co.,Ltd | 195.21 Million CNY | -427.119% |
| Shanghai Flyco Electrical Appliance Co., Ltd. | 806.72 Million CNY | -27.557% |
| Hangzhou Haoyue Personal Care Co., Ltd | 1.42 Billion CNY | 28.006% |